Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis

NCT01494857 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Adalimumab

Sponsor

Clalit Health Services